Page 18 - Sense Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

NeuroSense CEO to be Panelist at Cantor Neurology and Psychiatry Conference

Company s lead drug candidate PrimeC is currently being evaluated in a Phase IIb trial, with topline data expected in mid-2023CAMBRIDGE, Mass., Se.

United statesUniversity of arizonaUnited kingdomSan franciscoJeremy shefnerCantor fitzgeraldGregoryw fultonCharles duncanClinical trials consortiumDepartment of neurologyBarrow neurological instituteDrug administrationCantor healthcare teamNeurosense therapeutics ltdNeuromuscular disease centerEuropean medicines agency

NeuroSense Announces Positive PrimeC Pharmacokinetic Study Results & Anticipates Phase IIb ALS Enrollment to Expand into the US

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United kingdomFerenc tracikEuropean medicines agencyPrnewswire neurosense therapeutics ltdDrug administrationNeurosense therapeutics ltdSense therapeuticsChief medical officerOrphan drug designation

Neurosense Therapeutics (NRSN) Reports Positive PrimeC Pharmacokinetic Study Results, Plans Phase IIb ALS Enrollment to Expand into US

Neurosense Therapeutics (NRSN) Reports Positive PrimeC Pharmacokinetic Study Results, Plans Phase IIb ALS Enrollment to Expand into US
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Ferenc tracikDrug administrationNeurosense therapeutics ltdSense therapeuticsChief medical officer

NeuroSense Therapeutics to Present at Upcoming U S and European ALS Conferences

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

United kingdomUnited statesFernando vieiraSeanm healeyRobert brownSabrina paganoniJames berryFerenc tracikShiran zimriTherapy development institutePrnewswire neurosense therapeutics ltdDrug administrationHead of scientific program at neurosenseNeurosense therapeutics ltdResearch symposiumEuropean medicines agency

NeuroSense Announces Positive PrimeC Toxicology Data Supportive of Current Phase IIb PARADIGM ALS Clinical Trial

/PRNewswire/ NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today.

Ferenc tracikEuropean medicines agencyDrug administrationNeurosense therapeutics ltdChief medical officerOrphan drug designationSense therapeuticsNeurosense therapeuticNeurosense therapeutics